Insight

$Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS metastatic colorectal cancer$

Annie Xiao/cityofhope.org

Nov 11, 2024, 15:16

Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS metastatic colorectal cancer

Arndt Vogel, Managing Senior Consultant at Hannover Medical School, shared an article by Annie Xiao on X:

“Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS metastatic colorectal cancer in Oncology Advance.

phs-1, 39 pts.

ORR 36%, mPFS 5 & mOS 27.5 mo.

3-yr PFS rate 19.3 %.

some long-term responders, 3 w/ potential cure, we need a biomarker…”

$Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS metastatic colorectal cancer$

Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial.

Authors: Annie Xiao, et al.

$Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS metastatic colorectal cancer$

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.